| Literature DB >> 28570275 |
Soon Seng Ng1,2,3, Anming Xiong1,2, Khanh Nguyen1,2, Marilyn Masek1,2,4, Da Yoon No1,2,5, Menashe Elazar1,2, Eyal Shteyer6, Mark A Winters1,2, Amy Voedisch7, Kate Shaw7, Sheikh Tamir Rashid1,2, Curtis W Frank8, Nam Joon Cho3, Jeffrey S Glenn1,2.
Abstract
A major challenge for studying authentic liver cell function and cell replacement therapies is that primary human hepatocytes rapidly lose their advanced function in conventional, 2-dimensional culture platforms. Here, we describe the fabrication of 3-dimensional hexagonally arrayed lobular human liver tissues inspired by the liver's natural architecture. The engineered liver tissues exhibit key features of advanced differentiation, such as human-specific cytochrome P450-mediated drug metabolism and the ability to support efficient infection with patient-derived inoculums of hepatitis C virus. The tissues permit the assessment of antiviral agents and maintain their advanced functions for over 5 months in culture. This extended functionality enabled the prediction of a fatal human-specific hepatotoxicity caused by fialuridine (FIAU), which had escaped detection by preclinical models and short-term clinical studies. The results obtained with the engineered human liver tissue in this study provide proof-of-concept determination of human-specific drug metabolism, demonstrate the ability to support infection with human hepatitis virus derived from an infected patient and subsequent antiviral drug testing against said infection, and facilitate detection of human-specific drug hepatotoxicity associated with late-onset liver failure. Looking forward, the scalability and biocompatibility of the scaffold are also ideal for future cell replacement therapeutic strategies.Entities:
Keywords: Drug screens; Gastroenterology; Hepatitis; Infectious disease; Pharmacology
Year: 2017 PMID: 28570275 PMCID: PMC5453699 DOI: 10.1172/jci.insight.90853
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708